## Jaime H Vera

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2952675/publications.pdf

Version: 2024-02-01

394421 434195 1,320 80 19 31 citations h-index g-index papers 86 86 86 1926 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Strengths and Challenges of Various Models of Geriatric Consultation for Older Adults Living With Human Immunodeficiency Virus. Clinical Infectious Diseases, 2022, 74, 1101-1106.	5.8	14
2	The impact of COVIDâ€19 on HIV testing in the UK's first Fastâ€Track HIV city. HIV Medicine, 2022, 23, 790-7	79 <b>£</b> .2	5
3	Long COVID and episodic disability: advancing the conceptualisation, measurement and knowledge of episodic disability among people living with Long COVID – protocol for a mixed-methods study. BMJ Open, 2022, 12, e060826.	1.9	13
4	Evaluation of kidney function among people living with HIV initiating antiretroviral therapy in Zambia. PLOS Global Public Health, 2022, 2, e0000124.	1.6	1
5	Increasing access to HIV testing for men who have sex with men in Japan using digital vending machine technology. International Journal of STD and AIDS, 2022, 33, 680-686.	1.1	1
6	"A fog that impacts everything― a qualitative study of health-related quality of life in people living with HIV who have cognitive impairment. Quality of Life Research, 2022, 31, 3019-3030.	3.1	7
7	Neuroinflammation in HIV-associated depression: evidence and future perspectives. Molecular Psychiatry, 2022, 27, 3619-3632.	7.9	16
8	Respiratory symptoms and chronic bronchitis in people with and without HIV infection. HIV Medicine, 2021, 22, 11-21.	2.2	7
9	Agreement between self-reported and objective measures of sleep in people with HIV and lifestyle-similar HIV-negative individuals. Aids, 2021, 35, 1051-1060.	2.2	9
10	Sleep health and cognitive function among people with and without HIV: the use of different machine learning approaches. Sleep, 2021, 44, .	1.1	10
11	Quality of life in people living with HIV-associated neurocognitive disorder: A scoping review study. PLoS ONE, 2021, 16, e0251944.	2.5	21
12	Anal cancer screening in the UK: serial cross-sectional surveys on attitudes and practices. Sexually Transmitted Infections, 2021, 97, 394-394.	1.9	0
13	Clinical Utility of $\hat{I}^2$ -Amyloid PET Imaging in People Living With HIV With Cognitive Symptoms. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 87, 826-833.	2.1	5
14	Associations between plasma nucleoside reverse transcriptase inhibitors concentrations and cognitive function in people with HIV. PLoS ONE, 2021, 16, e0253861.	2.5	3
15	O17.5â€Blood borne viruses screening (BBVS) for temporarily housed rough sleepers in Brighton & amp; Hove during the Covid-19 pandemic., 2021, , .		0
16	Does duration of HIV infection substitute for age as a risk factor for amyloid deposition?. Aids, 2021, 35, 1501-1502.	2.2	1
17	"l have the strength to get through this using my past experiences with HIV― findings from a mixed-method survey of health outcomes, service accessibility, and psychosocial wellbeing among people living with HIV during the Covid-19 pandemic. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV. 2021 1-7.	1.2	10
18	Structured medicines reviews in HIV outpatients: a feasibility study (The MOR Study). HIV Medicine, 2021, , .	2.2	2

#	Article	IF	Citations
19	Sleep Disorders in Human Immunodeficiency Virus: A Substudy of the Pharmacokinetics and Clinical Observations in People Over Fifty (POPPY) Study. Open Forum Infectious Diseases, 2021, 8, ofaa561.	0.9	20
20	Correlation between computerised and standard cognitive testing in people with HIV and HIV-negative individuals. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2021, 33, 1296-1307.	1.2	1
21	Point-of-care testing for sexually transmitted infections in low- and middle-income countries: a scoping review protocol. JBI Evidence Synthesis, 2021, 19, 155-162.	1.3	2
22	Disability and self-care living strategies among adults living with HIV during the COVID-19 pandemic. AIDS Research and Therapy, 2021, 18, 87.	1.7	5
23	Global phylogeny of Treponema pallidum lineages reveals recent expansion and spread of contemporary syphilis. Nature Microbiology, 2021, 6, 1549-1560.	13.3	51
24	Cerebral function parameters in people with HIV switching integrase inhibitors: a randomized controlled trial. HIV Research and Clinical Practice, 2021, , 1-9.	1.1	0
25	The predictors of pain extent in people living with HIV. Aids, 2020, 34, 2071-2079.	2.2	9
26	Comorbidity indices in people with HIV and considerations for coronavirus disease 2019 outcomes. Aids, 2020, 34, 1795-1800.	2.2	7
27	Evaluation of a Combined HIV and Geriatrics Clinic for Older People Living with HIV: The Silver Clinic in Brighton, UK. Geriatrics (Switzerland), 2020, 5, 81.	1.7	19
28	Factors associated with obesity in the Pharmacokinetic and Clinical Observations in People over Fifty (POPPY) cohort: an observational crossâ€sectional analysis. HIV Medicine, 2020, 21, 441-452.	2.2	8
29	HIV self-tests for men who have sex with men, accessed via a digital vending machine: a qualitative study of acceptability. International Journal of STD and AIDS, 2020, 31, 420-425.	1.1	6
30	Changes in functional connectivity in people with HIV switching antiretroviral therapy. Journal of NeuroVirology, 2020, 26, 754-763.	2.1	9
31	Surveying testing preferences in Black, Latin American, and other minorities for the co-design of digital vending machines for HIV self-testing. International Journal of STD and AIDS, 2020, 31, 158-165.	1.1	8
32	Monitoring of older HIVâ€1â€positive adults by HIV clinics in the United Kingdom: a national quality improvement initiative. HIV Medicine, 2020, 21, 409-417.	2.2	4
33	AIDSImpact special issue – broadening the lens: recommendations from rehabilitation in chronic disease to advance healthy ageing with HIV. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2020, 32, 65-73.	1.2	16
34	Plasma nucleotide reverse transcriptase inhibitor concentration and their associations with liver and renal parameters in people living with HIV. Aids, 2020, 34, 790-793.	2.2	1
35	Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEATO22 Study. Clinical Infectious Diseases, 2019, 68, 597-606.	5.8	34
36	Increased Dolutegravir Peak Concentrations in People Living With Human Immunodeficiency Virus Aged 60 and Over, and Analysis of Sleep Quality and Cognition. Clinical Infectious Diseases, 2019, 68, 87-95.	5.8	49

#	Article	IF	Citations
37	Barriers to HIV care and adherence for young people living with HIV in Zambia and mHealth. MHealth, 2019, 5, 45-45.	1.6	26
38	Improved Central Nervous System Symptoms in People with HIV without Objective Neuropsychiatric Complaints Switching from Efavirenz to Rilpivirine Containing cART. Brain Sciences, 2019, 9, 195.	2.3	8
39	Polypharmacy and Drug–drug Interactions in Older and Younger People Living with HIV: The POPPY Study. Antiviral Therapy, 2019, 24, 193-201.	1.0	44
40	Physical activity and quality of life in people living with HIV. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2019, 31, 589-598.	1.2	24
41	Impact of musculoskeletal symptoms on physical functioning and quality of life among treated people with HIV in high and low resource settings: A case study of the UK and Zambia. PLoS ONE, 2019, 14, e0216787.	2.5	7
42	Cognitive function, depressive symptoms and syphilis in HIV-positive and HIV-negative individuals. International Journal of STD and AIDS, 2019, 30, 440-446.	1.1	8
43	Level of agreement between frequently used cardiovascular risk calculators in people living with HIV. HIV Medicine, 2019, 20, 347-352.	2.2	14
44	Depression, lifestyle factors and cognitive function in people living with ⟨scp⟩HIV⟨/scp⟩ and comparable ⟨scp⟩HIV⟨/scp⟩â€negative controls. HIV Medicine, 2019, 20, 274-285.	2.2	28
45	Assessment and Management of HIV-Associated Cognitive Impairment: Experience from a Multidisciplinary Memory Service for People Living with HIV. Brain Sciences, 2019, 9, 37.	2.3	22
46	Acceptability and feasibility of using digital vending machines to deliver HIV self-tests to men who have sex with men. Sexually Transmitted Infections, 2019, 95, 557-561.	1.9	15
47	Risk factors and impact of patterns of co-occurring comorbidities in people living with HIV. Aids, 2019, 33, 1871-1880.	2.2	18
48	Sporadic CJD in association with HIV. Journal of Neurology, 2019, 266, 253-257.	3.6	2
49	Highâ€risk behaviours, and their associations with mental health, adherence to antiretroviral therapy and <scp>HIV</scp> â€positive men who have sex with men. HIV Medicine, 2019, 20, 131-136.	2.2	8
50	Neurosyphilis in patients with HIV. Practical Neurology, 2018, 18, 211-218.	1.1	52
51	Global sexual health education: STIF in Zambia. Sexually Transmitted Infections, 2018, 94, 2-2.	1.9	0
52	Clinical use of brain magnetic resonance imaging for neurological symptoms in people living with <scp>HIV</scp> . HIV Medicine, 2018, 19, e66.	2.2	1
53	Measurement of Retinal Vessels as a Biomarker of Cerebrovascular Aging in Older HIV-Positive Men Compared With Controls. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 199-205.	2.1	7
54	Pain in people living with HIV and its association with healthcare resource use, well being and functional status. Aids, 2018, 32, 2697-2706.	2.2	47

#	Article	IF	Citations
55	Patterns of Co-occurring Comorbidities in People Living With HIV. Open Forum Infectious Diseases, 2018, 5, ofy272.	0.9	35
56	Cohort profile: The Pharmacokinetic and clinical Observations in PeoPle over fiftY (POPPY) study. International Journal of Epidemiology, 2018, 47, 1391-1392e.	1.9	33
57	Cognitive Impairment in people living with HIV in the ART era: A Review. British Medical Bulletin, 2018, 127, 55-68.	6.9	102
58	PET brain imaging in HIV-associated neurocognitive disorders (HAND) in the era of combination antiretroviral therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 895-902.	6.4	22
59	The management of comorbidities in older people living with <scp>HIV</scp> in England: a cross sectional survey. HIV Medicine, 2017, 18, 534-535.	2.2	0
60	Nanoflow-Nanospray Mass Spectrometry Metabolomics Reveals Disruption of the Urinary Metabolite Profiles of HIV-Positive Patients on Combination Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, e45-e53.	2.1	12
61	Associations between cognitive impairment and patientâ€reported measures of physical/mental functioning in older people living with HIV. HIV Medicine, 2017, 18, 363-369.	2.2	24
62	P3.129â€How can we use phylogenetics to facilitate clinical case finding and partner notification in hiv: lessons from a systematic review of its use in stigmatised infectious diseases. , 2017, , .		0
63	Highlights from the Conference on Retroviruses and Opportunistic Infections 2016. Journal of Virus Eradication, 2016, 2, 124-130.	0.5	0
64	Defining cognitive impairment in people-living-with-HIV: the POPPY study. BMC Infectious Diseases, 2016, 16, 617.	2.9	61
65	Atherosclerosis is Evident in Treated HIV-Infected Subjects With Low Cardiovascular Risk by Carotid Cardiovascular Magnetic Resonance. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 514-521.	2.1	16
66	Neuroinflammation in treated HIV-positive individuals. Neurology, 2016, 86, 1425-1432.	1.1	136
67	Highlights from the Conference on Retroviruses and Opportunistic Infections 2016: 22-25 February 2016, Boston, Massachusetts, USA. Journal of Virus Eradication, 2016, 2, 124-30.	0.5	O
68	The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60â€Syears of age. HIV Clinical Trials, 2015, 16, 39-42.	2.0	10
69	Can antiretroviral therapy prevent HIV-associated cognitive disorders?. Current Opinion in HIV and AIDS, 2014, 9, 11-16.	3.8	10
70	Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 2014, 69, 1642-1647.	3.0	29
71	Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects. Journal of Antimicrobial Chemotherapy, 2013, 68, 1348-1353.	3.0	12
72	The safety of flucloxacillin in HIV-infected patients with positive HLA-B*5701 genotype. Aids, 2013, 27, 484-485.	2.2	2

#	Article	IF	CITATIONS
73	Transient bone marrow oedema syndrome in an HIV-infected patient on highly active antiretroviral therapy. International Journal of STD and AIDS, 2012, 23, 213-215.	1.1	6
74	Alterations in Cerebrospinal Fluid Chemokines Are Associated With Maraviroc Exposure and In Vivo Metabolites Measurable by Magnetic Resonance Spectroscopy. HIV Clinical Trials, 2012, 13, 222-227.	2.0	12
75	Acute renal failure due to immune reconstitution inflammatory interstitial nephritis in an HIV-positive patient. Aids, 2010, 24, 1788-1790.	2.2	10
76	HIV and systemic lupus erythematosus: the clinical and diagnostic dilemmas of having dual diagnosis. International Journal of STD and AIDS, 2010, 21, 845-846.	1.1	10
77	Preservation of basophils in dapsoneâ€induced agranulocytosis suggests a possible pathogenetic role for leucocyte peroxidases. International Journal of Laboratory Hematology, 2009, 31, 245-247.	1.3	10
78	Current screening for HIV. BMJ: British Medical Journal, 2009, 338, b1500-b1500.	2.3	0
79	Heterogeneous nuclear ribonucleoprotein A2 is a SET-binding protein and a PP2A inhibitor. Oncogene, 2006, 25, 260-270.	5.9	29
80	Ophthalmoplegia and Slurred Speech in an Intravenous Drug User. PLoS Medicine, 2006, 3, e453.	8.4	4